The Clinical Professionals group aim to be aware of the latest industry events and news whilst also aspiring to be at the forefront of the latest analytics and reporting.This enables our consultants to provide a concise and quality service for both clients and candidates, whilst helping the industry to evolve as a whole. Consequently, the
The Clinical Professionals Group aim to provide candidates and clients with the best career advice and knowledge on recruitment by being attentive and responsive to the latest changes within life sciences. Our desire to be at the forefront of analysis and reporting allow us to provide the best service to all who conduct business with
After a period of speculation Pfizer has recently stepped forward with a $14-billion bid for Medivation, trouncing Sanofi and other suitors in a move designed to boost its oncology portfolio. Pfizer announced a definitive merger agreement under which it will acquire the US biopharma (which is currently focused on developing and commercialising small molecules for
Pfizer Inc. announced the recent publication of a post-hoc analysis of data from three studies of VYNDAQEL in patients with mild transthyretin familial amyloid polyneuropathy (TTR-FAP). The analysis, which included patients with the Val30Met mutation treated over varying periods of up to 5 and a half years, showed that treatment with VYNDAQEL initiated during the
Last month our CEO, Yvette Cleland, contributed her thoughts and opinions on the staff shortage crisis currently affecting the clinical research industry to a BioPharm Insight article: The CRO industry’s acute understaffing issue is likely to become more of a burden to sponsors and CROs as trial volumes increase while recruitment stagnates, said experts. While the
On Thursday June 23rd 2016, the UK voted in tens of millions on whether the UK should remain within the European Union. The following day it was announced that the UK will be set to leave the EU with the votes swaying 51.9% for leave and 48.1% for remain, with a 72.2% turnout. In light
Celgene and Jounce Therapeutics are to join in a global strategic collaboration with the aim of developing and commercialising immuno-oncology treatments. The collaboration will provide Celgene the options to jointly develop and commercialise Jounce’s primary product candidate, JTX-2011, and other innovative immunotherapies targeting B cells, T regulatory cells and tumor-associated macrophages.
Merck and non-profit organisation International Vaccine Institute (IVI) based in Seoul, South Korea, are collaborating to develop a more robust and scalable vaccine manufacturing processes. Merck will provide funding and expertise in areas of clarification and purification under a new research agreement between the two.
French bionic vision system firm, Pixium Vision has received approval from UK’s MHRA to start a clinical trial for patients who have lost sight due to retinitis pigmentosa (a group of inherited conditions that lead to a gradual reduction in vision) with the IRIS II bionic vision system.
Lilly is hoping to launch 20 new molecular entities in the 2014 to 2023 timeframe, backed up by two new indications or line extensions each year, throughout its core therapeutic categories of diabetes, immunology, oncology, neurodegeneration and pain.
